Pernix Therapeutics Holdings (PTX) : 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Pernix Therapeutics Holdings (PTX). Zacks Investment Research suggests a Strong Sell with a rank of 5.The median of all the 2 Wall Street Analysts endorse the stock as a Hold with a rating of 3.
Also, Brokerage firm Brean Capital downgrades its rating on Pernix Therapeutics Holdings (NASDAQ:PTX). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on August 12, 2016.
Pernix Therapeutics Holdings (NASDAQ:PTX): After opening at $0.5301, the stock dipped to an intraday low of $0.52 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.56 and the buying power remained strong till the end. The stock closed at $0.554 for the day, a gain of 4.45% for the day session. The total traded volume was 2,326,067. The stocks close on the previous trading day was $0.5304.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).